Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study
Henri Montaudié(Hôpital l'Archet), Frédéric Peyrade(Centre Hospitalier Universitaire de Nantes), Anne-Bénédicte Duval-Modeste(Université de Rouen Normandie), F. Brunet‐Possenti(Inserm), N. Dupin(Hôpital Cochin), Régis Kaphan(Centre Hospitalier de Cannes), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Andrea Stefan(Université de Caen Normandie), Alexandra Picard‐Gauci(Université Côte d'Azur), P. Combemale(Centre Léon Bérard), Stéphane Dalle(Hospices Civils de Lyon), Laurent Mortier, Caroline Robert(Institut Gustave Roussy), Julien Viotti(Centre Antoine Lacassagne), Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), G. Poissonnet, Maria Kogay(Centre Antoine Lacassagne)
Cited by 56
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k